Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
We provide a medically supervised framework to ensure you lose weight safely and keep it off
Purpose-built for physicians GLP-1 use before weight-loss surgery rising, not linked to harmful outcomes Key takeaways: The use of GLP-1 receptor agonists in the year before weight-loss surgery rose more than threefold between 2018 and 2023
From 2.4% to 17.6% in Four Years A Truveta analysis of real-world data from January 2021 to September 2025 found that semaglutide or tirzepatide prescribing among women with PCOS rose from 2.4% in 2021 to 17.6% in 2025 more than a seven-fold increase
With the birth of her second childdaughter Adira in 2023Serena initially lost weight quickly, but she once again plateaued
Despite the fact that they're often referred to as "natural" alternatives to GLP-1 agonist medications, Metzgar says it's important to differentiate between the two
